Amarin Corporation plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amarin Corporation plc
Plus deals from Huadong/Arcutis, SK Bioscience/Novavax, NeuroBio/MThera, CASI/Mundipharma/Acrotech, Amarin/Lotus and Synergy/Livzon.
Amarin’s management has suggested that it would be prepared to compete “very aggressively” with a US authorized generic version of its Vascepa if and when it decides to launch. The comments came as the originator named a new CEO and restructured in the wake of increasing generic competition.
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
Highlighted by SK Biopharmaceuticals’ recent decision to acquire the US-based ProteoVant Sciences, Korean pharma firms are stepping up deals and collaborations in the hot TPD space, which is expected to continue to attract global investors and big pharma interest.
- Other Names / Subsidiaries
- Amarin Pharma
- Amarin Pharmaceuticals Ireland Limited
- Laxdale Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.